Sagent Pharmaceuticals Announces Launch of Octreotide Acetate Injection

Sagent Pharmaceuticals

today announced the launch of Octreotide Acetate Injection, a Somatostatin Analog, in five vial presentations. According to IMS, for the 12 months ending October 2013, the US market for Octreotide Acetate Injection approximated $45 million. As with all products in Sagent's portfolio, Octreotide features the company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.